For the readers interested in the stock health of Rhythm Pharmaceuticals Inc. (RYTM). It is currently valued at $26.90. When the transactions were called off in the previous session, Stock hit the highs of $23.89, after setting-off with the price of $22.12. Company’s stock value dipped to $20.83 during the trading on the day. When the trading was stopped its value was $23.09.
Recently in News on August 6, 2020, Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference. Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm, and Hunter Smith, Chief Financial Officer, will present a corporate overview at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 9:30 a.m. ET. You can read further details here
Rhythm Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $27.97 on 08/28/20, with the lowest value was $12.99 for the same time period, recorded on 03/16/20.
Rhythm Pharmaceuticals Inc. (RYTM) full year performance was 3.40%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Rhythm Pharmaceuticals Inc. shares are logging 4.02% during the 52-week period from high price, and 107.08% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $12.99 and $25.86.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 911792 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Rhythm Pharmaceuticals Inc. (RYTM) recorded performance in the market was 0.57%, having the revenues showcasing 19.08% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.03B, as it employees total of 70 workers.
Analysts verdict on Rhythm Pharmaceuticals Inc. (RYTM)
During the last month, 0 analysts gave the Rhythm Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.12, with a change in the price was noted +11.08. In a similar fashion, Rhythm Pharmaceuticals Inc. posted a movement of +70.48% for the period of last 100 days, recording 208,366 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RYTM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Rhythm Pharmaceuticals Inc. (RYTM): Technical Analysis
Raw Stochastic average of Rhythm Pharmaceuticals Inc. in the period of last 50 days is set at 88.26%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.26%. In the last 20 days, the company’s Stochastic %K was 71.73% and its Stochastic %D was recorded 47.89%.
Let’s take a glance in the erstwhile performances of Rhythm Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 0.57%. Additionally, trading for the stock in the period of the last six months notably improved by 21.02%, alongside a boost of 3.40% for the period of the last 12 months. The shares increased approximately by 23.15% in the 7-day charts and went up by 11.87% in the period of the last 30 days. Common stock shares were driven by 19.08% during last recorded quarter.